Merck & Co., Inc: Diabetes Mellitus, Type 2 trials
The registry lists 181 Diabetes Mellitus, Type 2 studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 150 have results posted.
Phase 1 55Phase 2 21Phase 3 86Phase 4 6No phase 13(a study in two phases counts in both)
Studies
Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)CompletedNCT00813995Phase 3Results posted
- Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)TerminatedNCT00806585Phase 2Results posted
- A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)CompletedNCT00792935Phase 2Results posted
- MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)CompletedNCT00791661Phase 1Results posted
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED)CompletedNCT00790556Phase 1Results posted
- Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)CompletedNCT00790205Phase 3Results posted
- Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)TerminatedNCT00767000Phase 2Results posted
- A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)TerminatedNCT00758680Phase 1Results posted
- Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)CompletedNCT00758069Phase 2Results posted
- A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED)CompletedNCT00757601Phase 1Results posted
- MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).CompletedNCT00754130Phase 1Results posted
- A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)CompletedNCT00730275Phase 1Results posted
- MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)CompletedNCT00722371Phase 3Results posted
- Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)CompletedNCT00704132Phase 1Results posted
- A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)CompletedNCT00701090Phase 3Results posted
- Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338)(COMPLETED)CompletedNCT00673465Phase 1Results posted
- A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)CompletedNCT00631488Phase 2Results posted
- A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)CompletedNCT00618995Phase 1Results posted
- Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)CompletedNCT00567112Phase 1Results posted
- Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)CompletedNCT00545584Phase 3Results posted
- Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)CompletedNCT00541775Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)CompletedNCT00541450Phase 3Results posted
- Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)CompletedNCT00541229Phase 1Results posted
- MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)CompletedNCT00532935Phase 3Results posted
- A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)CompletedNCT00511667Phase 1Results posted
- An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)CompletedNCT00511472Phase 1Results posted
- Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)CompletedNCT00511108Phase 1Results posted
- Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)CompletedNCT00509262Phase 3Results posted
- Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)CompletedNCT00509236Phase 3Results posted
- Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)CompletedNCT00485758Phase 3Results posted
- MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)CompletedNCT00482729Phase 3Results posted
- Dose-Range Finding Study for MK0893 (0893-008)TerminatedNCT00479466Phase 2Results posted
- Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)CompletedNCT00449930Phase 3Results posted
- A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)CompletedNCT00411554Phase 3Results posted
- Initial Combination With Pioglitazone Study (0431-064)CompletedNCT00397631Phase 3Results posted
- Sitagliptin Added-on to Insulin Study (0431-051)CompletedNCT00395343Phase 3Results posted
- MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)CompletedNCT00372060Phase 3Results posted
- Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)CompletedNCT00350779Phase 3Results posted
- Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes MellitusCompletedNCT00337610Phase 3Results posted
- Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)CompletedNCT00305604Phase 3Results posted
- MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)CompletedNCT00289848Phase 3Results posted
- A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)CompletedNCT00127192Phase 2Results posted
- Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)CompletedNCT00106704Phase 3Results posted
- MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)CompletedNCT00103857Phase 3Results posted
- An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)CompletedNCT00095056Phase 3Results posted
- An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)CompletedNCT00094770Phase 3Results posted
- An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)CompletedNCT00094757Phase 3Results posted
- Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)CompletedNCT00087516Phase 3Results posted
- Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)CompletedNCT00086515Phase 3Results posted
- Pioglitazone Add-on Study in Patients With Type 2 Diabetes MellitusCompletedNCT00086502Phase 3Results posted
- A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)CompletedNCT07242469Phase 1
- Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)CompletedNCT07089784Phase 1
- Telemonitoring System Study in Participants With Type 2 Diabetes Mellitus (MK-0000-347)CompletedNCT02194608Not applicable
- A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)CompletedNCT02012166Phase 1
- A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)TerminatedNCT01614782Phase 1
- Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)CompletedNCT01223339Phase 1
- A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)CompletedNCT01127308Phase 1
- Januvia Re-examination Study (MK-0431-181)CompletedNCT01062048
- A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)CompletedNCT00989079Phase 1
- A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)CompletedNCT00975052Phase 1
- A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)CompletedNCT00961857Phase 1
- A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)CompletedNCT00961480Phase 1
- Gut Hormone Profiling in Obese Patients With Type 2 Diabetes (MK-0000-134)CompletedNCT00957957
- A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002)TerminatedNCT00943371Phase 1
- Journey for Control of Diabetes Study (0431-111)CompletedNCT00652509Not applicable
- An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)CompletedNCT00642798Phase 1
- Dyslipidemia in Type 2 Diabetes (0767-034)TerminatedNCT00547274Phase 3
- Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)TerminatedNCT00543959Phase 2
- MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)TerminatedNCT00543816Phase 3
- Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)TerminatedNCT00543751Phase 3
- MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)CompletedNCT00543595Phase 2
- MK0767 in Type 2 Diabetes (0767-012)TerminatedNCT00543556Phase 2
- Study A - MK0767 Monotherapy StudyTerminatedNCT00543517Phase 3
- MK0767 and Sulfonylurea Combination Study (0767-027)TerminatedNCT00543491Phase 3
- Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)TerminatedNCT00543361Phase 3
- MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)TerminatedNCT00543010Phase 3
- A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)CompletedNCT00482079Phase 2
- A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)CompletedNCT00481663Phase 2
- An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)TerminatedNCT00430742Phase 3
- MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)CompletedNCT00371007Phase 2
- An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)TerminatedNCT00130806Phase 3